Effect of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC
10.3760/cma.j.issn.1008-6706.2020.03.016
- VernacularTitle: 强化热疗辅助小剂量顺铂化疗联合放疗治疗局部晚期非小细胞肺癌的疗效观察
- Author:
Luqing CHEN
1
;
Min WANG
;
Wanli ZHOU
;
Fajun XIANG
;
Dejuan HAN
;
Zhenyou SUN
;
Guowei LIU
;
Hongsheng GAO
Author Information
1. Department of Radiotherapy, the Second People's Hospital of Weifang, Weifang, Shandong 261041, China
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Diathermy;
Radiotherapy;
Cisplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(3):322-325
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect and safety of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC.
Methods:From January 2012 to December 2015, 104 patients with locally advanced NSCLC were chosen in the Second People's Hospital of Weifang and randomly divided into two groups according to the digital table, with 52 patients in each group.The control group was given low-dose cisplatin plus radiotherapy, and the observation group was given intensive hyperthermia on the basis of control group.The ORR, DCR, median OS, median PFS, KPS score, the levels of coagulation function index and tumor markers before and after treatment and incidence of side effects in the two groups were compared.
Results:The DCR of the observation group was significantly higher than that of the control group(86.54% vs.69.23%, χ2=8.24, P<0.05). The median OS and median PFS of the observation group were significantly longer than those of the control group(11.9 months vs.8.3 months; 7.5 months vs.4.7 months, t=2.56, 3.01, P<0.05). The KPS scores after treatment of the observation group were significantly higher than those of the control group and before treatment[(75.49±8.94)points vs.(68.65±7.06)points; (75.49±8.94)points vs.(62.23±6.34)points, t=2.78, 5.11, all P<0.05]. The levels of coagulation function index and tumor markers after treatment of the observation group were significantly lower than those of the control group and before treatment(t=3.14, 2.67, 3.59, 7.31; 4.89, 4.02, 4.70, 9.21; 2.44, 2.60, 3.20; 3.15, 3.78, 4.06; all P<0.05). There was no statistically significant difference in the incidence of side effects between the two groups(P>0.05).
Conclusion:Intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC can efficiently control disease progress, increase survival benefits, higher quality of life, improve coagulation function, reduce the levels of tumor markers and possess satisfactory safety.
